Multiple Reaction Monitoring Profiling (MRM-Profiling) of Lipids To Distinguish Strain-Level Differences in Microbial Resistance in Escherichia coli by Xie, Zhuoer et al.
Multiple Reaction Monitoring Profiling (MRM-Profiling) of Lipids to Distinguish Strain-
Level Differences in Microbial Resistance in Escherichia coli
Zhuoer Xie†, L. Edwin Gonzalez†, Christina R. Ferreira†,‡, Anna Vorsilak§, Dylan Frabutt§, Tiago J. P. Sobreira‡, 
Michael Pugia*,§, and R. Graham Cooks*,†
† Department of Chemistry, Purdue University, West Lafayette, Indiana 47907, United States
‡ Bindley Bioscience Center, Purdue University, West Lafayette, Indiana 47907, United States
§ Indiana Biosciences Research Institute, Indianapolis, Indiana 46202, United States
ABSTRACT: The worldwide increase in antimicrobial resistance is due to antibiotic over-use in agriculture and 
over-prescription in medicine. For appropriate and timely patient support, faster diagnosis of antimicrobial 
resistance is required. Current methods for bacterial identification rely on genomics and proteomics and use 
comparisons with databases of known strains, but the diagnostic value of metabolites and lipids has not been 
explored significantly. Standard mass spectrometry/chromatography methods involve multiple dilutions during 
sample preparation and separation. To increase the amount of chemical information acquired and the speed of 
analysis of lipids, multiple reaction monitoring profiling (MRM-Profiling) has been applied. The MRM-Profiling 
workflow includes a discovery stage and a screening stage. The discovery stage employs precursor ion (PREC) 
and neutral loss (NL) scans to screen representative pooled samples for functional groups associated with 
particular lipid classes. The information from the first stage is organized in precursor/product ion pairs, or 
MRMs, and the screening stage rapidly interrogates individual samples for these MRMs. In this study, we 
performed MRM-Profiling of lipid extracts from four different strains of Escherichia coli cultured with amoxicillin 
or amoxicillin/clavulanate, a beta-lactam and beta-lactamase inhibitor, respectively. T-tests, analysis of variance 
(ANOVA) and receiver operating characteristic (ROC) curves were used to determine the significance of each 
MRM. Principal component analysis (PCA) was applied to distinguish different strains cultured under conditions 
that allowed or disallowed development of bacterial resistance. The results demonstrate that MRM-Profiling 
distinguishes the lipid profiles of resistant and non-resistant E. coli strains.
Annually there are over 1.2 billion health care visits in the United States of which 12.6% result in ~154 million 
antibiotic prescriptions for bacterial infections.1 Urinary, respiratory and skin infections are most common.2 The 
top pathogens responsible for 80 to 90% of infections are Escherichia coli, Staphylococcus aureus, and Klebsiella 
pneumoniae, the latter two of which are part of the ESKAPE group of pathogens which also include Enterococcus 
faecium, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species.3–5 Infections are 
especially common in certain care settings and patient populations where they cause high recurrence rates and 
great severity of infections.6–8 Potential infections are frequently treated prior to confirmation of the presence 
of pathogens, leading to over-prescription which is strongly associated with the development of antibiotic-
resistance and may eradicate potentially commensal microbiome populations, resulting in dysfunction against 
future pathogens.9–12 High rates of infection recurrence and the emergence of pathogens with antimicrobial 
resistance are found among patients with frequent antibiotic dosing.11,13,14 There therefore remains a need for 
rapid bacterial identification to help suppress this process.
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2In current clinical settings, the identification of bacteria is usually determined based on phenotype and/or 
genotype. Culture-based phenotyping methods are commonly used in clinical laboratories.15,16 Molecular 
diagnosis, including sequencing of ribosomal genes,17 whole genome sequencing,18,19 and amplification 
methods,20 represents an alternative strategy for bacterial typing. Current MS-based typing methods are largely 
focused on the protein profile with an emphasis on ribosomal proteins.16 In the last decade, matrix assisted 
laser desorption/ionization coupled with time-of-flight mass spectrometry (MALDI-TOF MS) has been applied 
successfully using  relatively simple sample preparations to acquire fingerprint mass spectra and accomplish 
identification by database searches.21–23 Several commercial platforms have emerged and profoundly changed 
the state of clinical testing. In addition, tandem MS with or without liquid chromatography has also been used 
with great success.24–26
Metabolomics, which covers a wide range of small molecules but is not widely applied to bacterial 
identification, is an appealing and emerging field of omics in biomarker discovery by MS.27–30 Lipids are believed 
to play an indispensable metabolic role in many essential biological processes. In microorganisms, the diversity 
in structures and the complexity of biosynthesis pathways of bacterial lipids enable bacterial cells to adjust their 
lipid profiles in response to environmental changes, including antibiotic treatment.31–33 Conventional lipid 
pathway analysis involves extensive sample preparation and complex protocols for the characterization of 
potential lipid biomarkers.34,35 The unclear relationship between lipids and molecular function further slows 
down the pace of development of analytical methods. To accelerate exploratory lipidomic discovery, a novel 
two-stage methodology, multiple reaction monitoring profiling (MRM-Profiling), has been developed as a 
diagnostic/distinguishing factor. It has previously been tested on several model systems, including Parkinson’s 
disease,36 polycystic ovarian syndrome,37 diet compliance,38 colostrum uptake,39 atopic dermatitis,40 and embryo 
metabolism.41 The results of MRM-Profiling have proven to be broadly consistent with those from pathological 
or clinical analysis.
Here we report a study on the feasibility of using MRM-Profiling to differentiate lipid profile differences among 
bacterial strains with different antimicrobial resistance. Lipid extracts of bacteria were analyzed using 
electrospray ionization MS (ESI-MS), screened by precursor ion and neutral loss scans and discriminated using 
PCA. The experiments focused on glycerophospholipids and sphingolipids. Statistical analytical methods, 
specifically the t-test and ROC curves, provided details as to which of the MRMs were most informative. 
Additionally, lipid differences observed among bacteria treated using various concentrations of amoxicillin and 
amoxicillin/clavulanate indicated that lipid profiles are modulated by environmental changes. The lipid 
composition of bacterial lysates was found to allow discrimination between resistant and non-resistant E. coli 
strains.
EXPERIMENTAL SECTION
Chemicals. All chemicals were all purchased from Sigma-Aldrich Co. LLC (St. Louis, MO) except that clavulanate 
was purchased from Cresent Chemical (Bangladesh).
Bacterial Culture. Non-resistant E. coli strains (ATCC® 25922™, CDC AR-bank #0077, ATCC® 4157™) and resistant 
strains with beta-lactam resistance gene CTX-M-14 or 15 (CDC AR-bank #0086, CDC AR-bank #0162, CDC AR-
bank #0151) were obtained from the ATCC or the CDC and FDA antibiotic resistance isolate bank. Bacterial 
stocks, stored at -80°C until usage, were generated from tryptic soy broth (TSB) (Becton Dickinson, Franklin 
Lakes, NJ) cultures inoculated with a single colony taken from streak plate isolates from the supplier’s stock on 
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3tryptic soy agar (TSA) (Becton Dickinson, Franklin Lakes, NJ). Fresh bacteria were cultured from stock by gentle 
scraping with a sterile implement off the top of the stock and by streaking onto a fresh TSA plate for single 
colony growth, which was incubated for 15 hours at 37°C. A single colony was then re-streaked onto a fresh TSA 
plate and was incubated for 15 hours at 37°C. Bacterial titer was estimated by resuspending morphologically 
similar colonies into 20mL of fresh TSB and by measuring optical density at 600nm (OD600) absorbance readings 
using a BioTek Synergy HTX multi-mode plate reader (BioTek, Winooski, VT) with McFarland standards (Scientific 
Device Laboratory, Inc., Des Plaines, IL). Verification of culture concentrations was performed with a ten-fold 
serial dilution in TSB; a 1.0 µL loopful from each dilution was streaked onto BD BBL™ Trypticase™ Soy Agar 
plates (Becton, Dickinson and Co., Franklin Lakes, NJ), and colonies were counted after incubation at 37°C for 16 
hours.
Minimum Inhibitory Concentration Test. A standard 96-well plate-based minimum inhibitory concentration 
(MIC) test was used to measure antibiotic efficiency of amoxicillin and amoxicillin/clavulanate combination 
against bacteria in mono-culture. After overnight growth on the corresponding culture medium and OD600 
measurement, MIC testing was performed with cation-adjusted Mueller-Hinton broth. In a row of the plate, 11 
wells contained a starting culture at 5x105 cfu/mL challenged with decreasing antibiotic concentrations 
delivered by serial dilution (e.g. 128, 64, 32, 16, 8, 4, 2, 1, 0.5, 0.25, 0 µg/mL); the last well contained blank 
medium as a sterility control. The lowest antibiotic concentration at which no cell number increase was 
measured via OD600 after a 24-hour incubation was the MIC of the antibiotic for that bacterial strain. All MIC 
tests were conducted in compliance with Clinical Laboratory Standards Institute (CLSI) procedures of clinical 
testing. The determined values of MIC for each strain appear in Table S1.
Sample Preparation. Samples of specific types of bacteria and MIC concentrations were taken from culture 
medium, normalized to 107 cells/mL by OD600, and were lysed with sonication. Lysate of bacteria was collected 
and stored at -80 °C. Lipid extraction was accomplished using the Bligh-Dyer42 strategy. After drying, lipid 
extracts were redissolved in acetonitrile/methanol/300 mM ammonium acetate (3:6.65:0.35, v/v/v) and 
transferred into autosampler vials ready for analysis. The extract solution was diluted to 2.5×105 cells/μL in vial, 
which is equivalent to lipid extracts of 2×106 cells in each injection of 8 μL solution.
Multiple Reaction Monitoring Profiling. MRM-Profiling is a two-stage MS methodology that benefits from 
various scan modes in tandem mass spectrometry–especially PREC and NL. In the discovery stage, PREC, NL, and 
MRM methods are applied to representative samples, mostly focusing on recognition of functional groups 
present in glycerophospholipids, acyl-carnitines, ceramides, and acyl residues containing different number of 
carbons with various degree of unsaturation. Specifically, glycerophospholipids contain glycerophosphate (PA), 
glycerophosphocholine (PC), glycerophosphoethanolamine (PE), glycerophosphoglycerol (PG), 
glycerophosphoinositol (PI), and glycerophosphoserine (PS). The PREC and NL scans were used as sources of 
MRM transitions and this experimental data was supplemented by MRM transitions deduced from data in the 
online lipid database, LipidMaps. Altogether 32 NL scan methods, 33 PREC scan methods, and 13 MRM 
transitions, as listed in Table S2 were used to survey representative samples from E. coli strains CDC 0077 and 
CDC 0086 cultured without amoxicillin. Experiments were carried out using a triple quadrupole mass 
spectrometer, Agilent QQQ 6410 (Santa Clara, CA), equipped with Agilent G1367A 1100 series autosampler 
(Santa Clara, CA). Samples were introduced into the mass spectrometer by direct flow injection ESI, i.e. without 
chromatographic separation. The ESI voltage was -3.5 kV. Dwell time was 25 ms. Collision energy (in 
manufacturer’s unit) and other scan method details are in Table S2. For each scan method, 8 μL of sample was 
injected at a flow rate of 20 μL/min. After data acquisition, transitions that were at least 30% higher in ion 
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4counts than blank samples were selected. Other values of threshold or data filtering concepts could have been 
employed but the tradeoff between chemical information and total instrument time required had an effect on 
the next stage, therefore we chose to be conservative to avoid losing chemical information. In addition, since 
representative samples were used, which could not reflect the scope of lipid profiles of all strains, keeping more 
transitions is beneficial to retaining as much chemical information as possible. In total, 2,329 transitions, of 
which 1,900 were in the positive ion mode and 429 in the negative ion mode, resulted from the discovery stage. 
The distribution of MRMs among different classes of lipids or functional groups are shown in Figure S1 and 
Figure S2 for positive and negative ion modes, respectively. This list served as a pool of candidates for building 
up MRM methods for the next Screening stage. Selected transitions were then arranged into 9 MRM methods (7 
in positive ion mode, 2 in negative ion mode) to investigate individual samples using the same instrument 
parameters as used in the Discovery stage. Given that the screening time for each method is 3 minutes, this 
results in a total analysis time of 30 minutes to screen each sample.
Statistical Analysis. Raw data were processed using Proteo-Wizard to extract the ion signals of each transition. 
The lowest ion count was regarded as the noise level of instrument. The cutoff for the screening stage data was 
chosen as 3× noise intensity to remove uninformative transitions with low ion intensities. The resulting data was 
represented as a table of ion counts, in which columns were samples and rows were features (MRMs in this 
case). T-test, analysis of variance (ANOVA), PCA, and ROC curves were calculated and plotted using 
MetaboAnalyst. For PCA, ANOVA, and t-test, the original data were scaled by mean-centering and dividing the 
individual intensities by the standard deviation of each MRM. For the ROC curve, no scaling was applied and the 
area under the curve (AUC) was calculated for each MRM. The cutoff applied to the t-test and ANOVA was a 
false discovery rate (FDR) adjusted p-value (or q-value) of 0.05 throughout the data processing.
RESULTS AND DISCUSSION
Lipid Analysis of Non-resistant Strains. Lipid analysis was carried out for non-resistant strains (ATCC 25922 and 
ATCC 4157) to investigate the effect of antibiotic application. Both strains were cultured under five conditions: 
no amoxicillin or amoxicillin/clavulanate, amoxicillin at half MIC, amoxicillin at MIC, amoxicillin/clavulanate at 
half MIC, and amoxicillin/clavulanate at MIC. MRMs were filtered by ion counts and FDR adjusted p-value in 
ANOVA, and then analyzed by PCA. Figure 1 shows the PCA scores plots of both strains. In the PCA scores plot, 
each point represents an individual lipid extract sample from the cultured bacteria and the elliptical shaded area 
is the calculated 95% confidence region for each group. In the case of ATCC 25922 as shown in Figure 1(a) where 
197 MRMs were used, bacteria treated with amoxicillin or amoxicillin/clavulanate at MIC are well separated 
along principal component (PC) 1 from bacteria cultured at half MIC or without amoxicillin. PC1 and PC2 
contribute 76% to the total variance. This separation can be attributed to the nature and the amount of the 
antibiotic, which leads to bacterial growth inhibition and hence the observed changes in lipid profiles.
Similar separation due to treatment differences are observed in the non-resistant strain ATCC 4157 in Figure 
1(b). With the same data filters, 157 MRMs were selected. PC1 and PC2 cover 74% of the entire variance 
observed. Different from ATCC 25922, the group grown with amoxicillin at MIC clusters away from the other 
groups on the PC1 dimension in the score plot. Groups treated with amoxicillin/clavulanate tend to overlap on 
PC1, while control and half MIC amoxicillin are closer. The MIC amoxicillin/clavulanate group is differentiated by 
PC1 to be closer to groups treated with low concentration of amoxicillin, instead of merging with the MIC 
amoxicillin group as in ATCC 25922.
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5Lipid Profile Differences Between Non-Resistant and Resistant Bacterial Strains. The results of attempts to 
distinguish non-resistant and resistant strains are promising. The purpose of carrying out statistical analysis of 
different strains exposed to the same treatment is to identify transitions that are responsible for the separation 
between strains. Two non-resistant strains (ATCC 25922 and ATCC 4157) and two resistant strains (CDC 0162 
and CDC 0151) were cultured without amoxicillin or amoxicillin/clavulanate as controls or with 
amoxicillin/clavulanate at half MIC. Transitions related to acyl-carnitines were found to be inconsistent (data 
not shown) and were removed from the statistics to better concentrate on the pattern of significant 
phospholipid transitions. Initially, for the control group, 86 MRMs were used for the statistical analysis, from 
which 38 MRMs were then selected using the FDR adjusted p-value in ANOVA. From the PCA scores plot of 
these transitions shown in Figure 2(a), PC1 and PC2 contribute 57% to the total variance. The major separation 
occurs along PC1. Statistical analysis was also carried out in terms of distinguishing non-resistant and resistant 
strains by regrouping samples into two sets. Because PCA is an unsupervised method, the PCA scores plot 
remains the same regardless of the labels of each sample if the same set of data is used. We note that, in cases 
where no antibiotic stress was applied, resistant and non-resistant strains can be well differentiated by PCA. T-
tests and ROC curves can provide more insight into the differences between strains. T-test results (Figure 2(b)) 
imply that 20 transitions, all of which show up in the 35 MRMs in the previous analysis, are significant for the 
differentiation. PC1 and PC2 take up 67% of the variance. ROC curves can be used to determine important 
transitions that are potentially characteristic for each set. As shown in Figure S3, there are seven transitions 
with AUC above 0.9, including three from saturated fatty acyl chain residues, two from PS, one from PE, and one 
from PG. Transitions selected from each analysis and their corresponding functional group or lipid class are 
tabulated in Table S3.
Turning to antibiotic treated bacteria, after elimination of transitions from acyl-carnitines and using the same 
data filter, 86 MRMs were left. ANOVA and t-tests produced sets of 34 and 12 transitions with the same cutoff 
applied, respectively. From the PCA results in Figure S4, transitions selected from ANOVA do not provide perfect 
separation between ATCC 25922 and CDC 0162. Transitions from t-tests offer similar separation along PC1 and 
its first two PCs explain 82% of the total variance. However, the number of features is fewer than in the control 
set. Among the 12 significant MRMs, three MRMs are found to have AUC above 0.9 from ROC curve, including 
one from PE, one from 26:0 fatty acyl chain residue, and one from PG, as shown in Figure S5. Details of 
transitions from each analysis are listed in Table S4. Bacteria treated with amoxicillin/clavulanate at half MIC 
and the controls have similar lipid transitions determined to be responsible for the separation.
Lipids associated with each MRM are postulated from the characteristic PREC and NL scans, as tabulated in 
Table S5. Although the exact structure of the lipids associated with each transition could not be decided merely 
by the MS/MS experiment, it is the pattern of the entire set of selected transitions spread over nine methods 
that provides reliable differentiation between strains from multiple classes of lipids. The distribution among the 
lipid classes of the transitions selected from t-tests is shown in Figure 3. Application of amoxicillin/clavulanate 
resulted in an increase in the number of informative transitions in unsaturated fatty acyl chain residues and a 
decrease in those in saturated fatty acyl chain residues. The number of informative transitions from PS dropped 
significantly after antibiotic treatment. Additionally, the total number of significant transitions from 
glycerophospholipids is larger when no amoxicillin or amoxicillin/clavulanate are applied, implying that more 
glycerophospholipids are detected. This is consistent with previous research.43 In spite of these successes at 
differentiation, samples containing both resistant and non-resistant E. coli may be more difficult to distinguish.
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6Different from exact mass searches in the database as is done in proteomics, MRM-Profiling offers opportunity 
to investigate changes in functional groups with more confidence. The low resolution of the instrument and the 
use of direct analysis with MRM methods means that it is still possible that isomeric ion pairs exist. For example, 
PG (35:1) and PGo (36:1) have monoisotopic masses with close values at 762.5411 (C41H79O10P) and 762.5775 
(C42H83O9P), respectively. In the MRM method, with NH4Ac introduced into the spray, the ammonium adducts 
are predominant for PG, making the corresponding transitions appear as 780.5→591.5 for both molecules. 
Nevertheless, when analyzing a lipid extract, the neutral loss of 189 from the head group in PG is what one 
should focus on because both candidate ion pairs are PG. Although the number of antibiotics types is limited in 
current study, MRM-Profiling might be more sensitive and efficient than existing methods as there are more 
lipid molecules per cell and analysis of small molecules has advantages in ion transmission and ionization 
efficiency. This preliminary study has demonstrated the feasibility of distinguishing bacterial strains by carrying 
out MRM-Profiling to characterize lipid patterns.
CONCLUSIONS
We have demonstrated that MRM-Profiling can be applied to distinguish four different strains of E. coli, 
including two non-resistant and two resistant strains. Different strains are well differentiated by PCA using 
significant MRMs acquired from t-test. This indicates that the lipid profiles not only serve to characterize 
bacterial species, but they also change in resistant strains compared to non-resistant strains and they are 
sensitive to antibiotic challenge. Lipid biomarker candidates are also determined, and this tool can help zeroing 
in on the biomarkers most significant for the separation. Based on previous studies in other complex biological 
systems, MRM-Profiling could expedite and improve the identification of lipids related with resistance, 
virulence, and viability. As such it will help benchmark the gene pathway involved in the phenotypes as a novel 
approach to identify unique resistance genes.
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Figure 1. PCA scores plots of non-resistant bacterial strains a) ATCC 25922 and b) ATCC 4157 after various 
antibiotic treatments. The color-shaded areas are the calculated range with 95% confidence. Amoxicillin and 
clavulanate are abbreviated as Amox and Clav, respectively.
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Figure 2. PCA scores plots of control samples (no amoxicillin or amoxicillin/clavulanate applied) using transitions 
selected from a) ANOVA and b) t-test. Color-shaded areas are the calculated range with 95% confidence.
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Figure 3. Distribution of transitions selected from t-test between controls and sample treated with 
amoxicillin/clavulanate at half MIC. “Saturated Chain” refers to the saturated fatty acyl chain residues. 
“Unsaturated Chain” refers to fatty acyl chain residues with degree of unsaturation ranging from 1 to 5.
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